General News

Date	Title
May 21, 2018	Realm Therapeutics Presents Data Highlighting its Proprietary Immunomodulatory Technology's Potential in Acne and Psoriasis at IID 2018 MALVERN, Pa. , May 21, 2018 /PRNewswire/ -- Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today announces that the Company presented a poster at the 2018 International Investigative Dermatology
May 2, 2018	Realm Therapeutics Files Registration Statement with the U.S. SEC to Facilitate Nasdaq Listing of ADSs Representing Ordinary Shares MALVERN, Pa. , May 2, 2018 /PRNewswire/ -- Realm Therapeutics plc (AIM: RLM) (the Company), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today announces it has confidentially submitted a registration statement to the United States
April 26, 2018	Realm Therapeutics plc ("Realm Therapeutics", "Realm", or the "Company") Notice of Full Year 2017 Results MALVERN, Pa. , April 26, 2018 /PRNewswire/ -- Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, today announces that the Company expects to release its results for the year ended December 31, 2017 on
February 27, 2018	Realm Therapeutics Strengthens its Patent Portfolio with Two New USPTO Notice of Allowances MALVERN, Pa. , Feb. 27, 2018 /PRNewswire/ -- Realm Therapeutics plc (AIM:RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, announced today that the United States Patent and Trademark Office (USPTO) has issued notices of allowance
February 20, 2018	Realm Therapeutics to Present at the RBC Capital Markets 2018 Global Healthcare Conference MALVERN, Pa. , Feb. 20, 2018 /PRNewswire/ -- Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, announced today that Alex Martin , CEO, will be presenting at the RBC Capital Markets 2018 Global
February 15, 2018	Realm Therapeutics Highlights Strong 2017 Performance and Outlines 2018 Milestones Phase 2 Allergic Conjunctivitis Study Ahead of Schedule; Top-Line Results Anticipated by End of Q1 Phase 2 Atopic Dermatitis Study on Track with Top-Line Results Expected in Late Q3 Year-end 2017 Cash, Cash Equivalents and Short-term Investments Were $33.9 Million MALVERN, Pa. , Feb.
January 2, 2018	Realm Therapeutics to Present at the 5th Annual Dermatology Summit MALVERN, Pa., Jan. 2, 2018 /PRNewswire/ -- Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, is pleased to announce that Alex Martin, CEO, will be presenting at the 5 th Annual Dermatology Summit, an
December 12, 2017	Realm Therapeutics Announces First Patient Dosed in Phase 2 Study of PR013 for the Treatment of Allergic Conjunctivitis MALVERN, Pa. , Dec. 12, 2017 /PRNewswire/ -- Realm Therapeutics plc (AIM:RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, today announces the first patient has been dosed in its Phase 2 study of PR013, the Company's topical

Search Investor Relations